5 Results for "

normal hematopoietic stem cells

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "normal hematopoietic stem cells" in MCE Product Catalog:

7
7 Publications Verification
Cat. No.: HY-112904
CAS No.: 2375193-43-2
Purity:  99.08%
Target:  

p62 Autophagy

Research Areas:  

Cancer

XRK3F2 is a p62 (sequestosome-1) ZZ domain inhibitor that has specificity for the p62-ZZ domain over other p62 signaling domains. XRK3F2 blocks TNFα effects and upregulation in bone marrow stromal cells, and induces multiple myeloma cell apoptosis. XRK3F2 can be used for the research of multiple myeloma bone disease, acute myeloid leukemia, and multiple myeloma .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108420
CAS No.: 6314-70-1
Purity:  98.10%
Target:  

CDK

Research Areas:  

Cancer

INK4C-IN-2 is a p18 INK4C inhibitor. NK4C-IN-2 promotes hematopoietic stem cells (HSCs) division by inhibiting INK4C and activating CDK4/6, with an ED50 of 5.21 nM. INK4C-IN-2 shows no cytotoxic to normal 32D cells, HSCs, leukemia cell lines and myeloma cell lines .
loading...
    loading...
Cat. No.: HY-177632
CAS No.: 2304711-81-5
Synonyms: ION-935918; ION251
Target:  

IFNAR

Research Areas:  

Cancer

Frenlosirsen (ION-935918; ION251) is an antisense oligonucleotide and also an IRF4 inhibitor. Frenlosirsen inhibits the survival of malignant plasma cells, reduces the burden of myeloma progenitor cells and prevents disease recurrence. Frenlosirsen is applicable to myeloma-related research .
loading...
    loading...
Cat. No.: HY-177632A
CAS No.: 2304711-82-6
Synonyms: ION-935918 sodium; ION251 sodium
Target:  

IFNAR

Research Areas:  

Cancer

Frenlosirsen sodium (ION-935918 sodium; ION251 sodium) is an antisense oligonucleotide and also an IRF4 inhibitor. Frenlosirsen sodium inhibits the survival of malignant plasma cells, reduces the burden of myeloma progenitor cells and prevents disease recurrence. Frenlosirsen sodium is applicable to myeloma-related research .
loading...
    loading...
Cat. No.: HY-112904A
CAS No.: 2375193-42-1
Target:  

p62

Research Areas:  

Cancer

XRK3F2 free base is a p62 (sequestosome-1) ZZ domain inhibitor that has specificity for the p62-ZZ domain over other p62 signaling domains. XRK3F2 free base blocks TNFα effects and upregulation in bone marrow stromal cells, and induces multiple myeloma cell apoptosis. XRK3F2 free base can be used for the research of multiple myeloma bone disease, acute myeloid leukemia, and multiple myeloma .
loading...
    loading...